COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Taste Properties of HIV Inhibitor

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02608918
Recruitment Status : Completed
First Posted : November 20, 2015
Last Update Posted : April 18, 2018
Senopsys, LLC
Information provided by (Responsible Party):
ViiV Healthcare

Brief Summary:
The purpose of the study is to assess the taste properties of HIV inhibitor

Condition or disease Intervention/treatment Phase
HIV Infections Drug: BMS-955176 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 8 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: An Open-Label Taste Assessment of BMS-955176 in Healthy Subjects
Actual Study Start Date : January 5, 2016
Actual Primary Completion Date : May 24, 2016
Actual Study Completion Date : May 24, 2016

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: BMS-955176
BMS-955176 specified dose on specified days
Drug: BMS-955176
Other Name: HIV Maturation Inhibitor

Primary Outcome Measures :
  1. Taste properties of HIV Inhibitor will be measured using the Flavor Profile of the Flavor Leadership Criteria [ Time Frame: Up to 2 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   25 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

For more information regarding BMS clinical trial participation, please visit

Inclusion Criteria:

  • Men and women of non-childbearing potential professional sensory panelists
  • Aged between 25 and 80 years

Exclusion Criteria:

  • History of relevant drug or food allergies, cardiovascular or Central nervous system (CNS) disease, clinically significant pathology, history of mental illness
  • Positive HIV test

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02608918

Layout table for location information
United States, Massachusetts
GSK Investigational Site
Woburn, Massachusetts, United States, 01801
Sponsors and Collaborators
ViiV Healthcare
Senopsys, LLC
Layout table for investigator information
Study Director: Viiv Clinical Trials ViiV Healthcare

Additional Information:
Layout table for additonal information
Responsible Party: ViiV Healthcare Identifier: NCT02608918    
Other Study ID Numbers: 206301
AI468-065 ( Other Identifier: Bristol-Myers Squibb )
First Posted: November 20, 2015    Key Record Dates
Last Update Posted: April 18, 2018
Last Verified: April 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents